Examining the association between oncology drug clinical benefit and the time to public reimbursement-Reference-Cited by-同舟云学术

Examining the association between oncology drug clinical benefit and the time to public reimbursement

Published:2021-12 Issue:2 Volume:11 Page:380-391
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Thomson Sasha¹,Everest Louis¹,Witzke Noah¹,Jiao Tina¹,Delos Santos Seanthel¹,Nguyen Vivian¹,Cheung Matthew C.¹²³^ORCID,Chan Kelvin K. W.¹²³⁴^ORCID

Affiliation:

1. Evaluative Clinical Sciences Odette Cancer Centre Research Program Sunnybrook Research Institute Toronto Ontario Canada

2. Odette Cancer Centre Sunnybrook Health Sciences Centre Toronto Ontario Canada

3. Department of Medicine University of Toronto Toronto Ontario Canada

4. Canadian Centre for Applied Research in Cancer Control Toronto Ontario Canada

Funder

Canadian Cancer Society

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4455

Reference31 articles.

1. BakerA.Book Crossing the Quality Chasm: A New Health System for the 21st Century. Vol 323. National Academies Press;2001. doi:10.1136/bmj.323.7322.1192

2. Expedited Programs for Serious Conditions––Drugs and Biologics|FDA.https://www.fda.gov/regulatory‐information/search‐fda‐guidance‐documents/expedited‐programs‐serious‐conditions‐drugs‐and‐biologicsAccessed December 12 2019

3. Guidance Document: Notice of Compliance with Conditions (NOC/c) ‐ Canada.ca.https://www.canada.ca/en/health‐canada/services/drugs‐health‐products/drug‐products/applications‐submissions/guidance‐documents/notice‐compliance‐conditions.htmlAccessed August 28 2020

4. Health Canada’s Use of its Notice of Compliance With Conditions Drug Approval Policy: A Retrospective Cohort Analysis

5. Efficacy, Safety, and Regulatory Approval of Food and Drug Administration–Designated Breakthrough and Nonbreakthrough Cancer Medicines

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early Access for Medicines in ITALY: The Case of Ruxolitinib for Patients with Graft-Versus-Host Disease;Journal of Clinical Medicine;2024-07-22

2. First-Line Tislelizumab for Advanced or Metastatic Esophageal Squamous Cell Carcinoma:A Cost-Effectiveness Analysis;Expert Review of Pharmacoeconomics & Outcomes Research;2023-11-30

3. Cost–effectiveness analysis of serplulimab as first-line treatment for advanced esophageal squamous cell carcinoma;Immunotherapy;2023-09

4. Access to novel cancer medicines in four countries in Central and Eastern Europe in relation to clinical benefit;ESMO Open;2023-08

5. Time to reimbursement of novel anticancer drugs in Europe: a case study of seven European countries;ESMO Open;2023-04